Table 1. Comparison of baseline characteristics and liver enzyme in Legalon and placebo groups.
| Legalon (n=45) | Placebo (n=58) | p-value | |
|---|---|---|---|
| Male sex | 28 (62.22) | 40 (68.97) | 0.474 |
| Age, yr | 57.73±13.94 | 58.53±14.71 | 0.778 |
| BMI, kg/m2 | 21.73±0.409 | 21.00±0.402 | 0.209 |
| HBsAg | 1 (2.22) | 3 (5.17) | 0.442 |
| Anti-HCV | 2 (4.44) | 1 (1.72) | 0.415 |
| Baseline | |||
| T.Bil, mg/dL | 0.65±0.336 | 0.67±0.263 | 0.719 |
| ALP, IU/L | 86.67±26.51 | 92.47±15.19 | 0.227 |
| AST, IU/L | 21.42±8.09 | 24.258±15.19 | 0.227 |
| ALT, IU/L | 20.266±13.69 | 18.655±9.746 | 0.506 |
| GGT, IU/L | 30.568±56.95 | 27.31±34.71 | 0.738 |
| Week 2 | |||
| T.Bil, mg/dL | 0.753±0.242 | 0.733±0.224 | 0.657 |
| ALP, IU/L | 93.067±29.636 | 96.67±29.796 | 0.543 |
| AST, IU/L | 24.956±8.790 | 30.448±24.376 | 0.153 |
| ALT , IU/L | 21.867±12.302 | 24.293±19.234 | 0.438 |
| GGT, IU/L | 38.533±31.583 | 36.879±30.205 | 0.805 |
| Week 4 | |||
| T.Bil, mg/dL | 0.756±0.230 | 0.8±0.295 | 0.406 |
| ALP, IU/L | 90.227±27.355 | 89.52±29.039 | 0.901 |
| AST, IU/L | 31.289±20.499 | 33.07±25.605 | 0.697 |
| ALT, IU/L | 27.444±3.144 | 27.175±22.421 | 0.95 |
| GGT, IU/L | 39.068±27.286 | 34.491±24.302 | 0.383 |
| Week 8 | |||
| T.Bil, mg/dL | 0.756±0.252 | 0.777±0.277 | 0.684 |
| ALP, IU/L | 83.222±25.971 | 83.075±27.253 | 0.978 |
| AST, IU/L | 36.756±25.414 | 42.340±78.974 | 0.627 |
| ALT , IU/L | 38.511±44.001 | 36.981±61.967 | 0.887 |
| GGT, IU/L | 42.156±40.880 | 46.622±79.706 | 0.722 |
Values are presented as number (%) or mean±SD.
BMI: body mass index; HBsAg: hepatitis B surface antigen; HCV: hepatitis C virus; T.Bil: total bilirubin; ALP: alkaline phosphatase; AST: aspartate aminotransferase; ALT: alanine transaminase; GGT: gamma glutamyl transferase.